DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: TYSABRI (natalizumab)
       *****************************************************
       #Post#: 853--------------------------------------------------
       (Abst.) Tysabri improves cognitive impairment over 3 years in
       MS...
   DIR By: agate
       Date: July 7, 2015, 11:51 am
       ---------------------------------------------------------
       From PubMed, July 7, 2015:
       --- Quote ---
       > PLoS One. 2015 Jul 6;10(7):e0131803.
       >
       > Natalizumab Significantly Improves Cognitive Impairment over
       Three Years in MS: Pattern of Disability Progression and
       Preliminary MRI Findings
       >
       > Mattioli F1, Stampatori C1, Bellomi F1, Scarpazza C1, Capra
       R2.
       >
       > Author information
       >
       > 1Neuropsychology Unit, Spedali Civili of Brescia, Brescia,
       Italy.
       > 2Multiple Sclerosis Center of the Spedali Civili of Brescia,
       Montichiari, Italy.
       >
       > Previous studies reported that multiple sclerosis (MS)
       patients treated with natalizumab for one or two years exhibit a
       significant reduction in relapse rate and in cognitive
       impairment, but the long term effects on cognitive performance
       are unknown.
       >
       > This study aimed to evaluate the effects of natalizumab on
       cognitive impairment in a cohort of 24 consecutive patients with
       relapsing remitting MS treated for 3 years.
       >
       > The neuropsychological tests, as well as relapse number and
       EDSS, were assessed at baseline and yearly for three years. The
       impact on cortical atrophy was also considered in a subgroup of
       them, and are thus to be considered as preliminary.
       >
       > Results showed a significant reduction in the number of
       impaired neuropsychological tests after three years, a
       significant decrease in annualized relapse rate at each time
       points compared to baseline and a stable EDSS.
       >
       > In the neuropsychological assessment, a significant
       improvement in memory, attention and executive function test
       scores was detected.
       >
       > Preliminary MRI data show that, while GM volume did not change
       at 3 years, a significantly greater parahippocampal and
       prefrontal gray matter density was noticed, the former
       correlating with neuropsychological improvement in a memory
       test.
       >
       > This study showed that therapy with Natalizumab is helpful in
       improving cognitive performance, and is likely to have a
       protective role on grey matter, over a three-year follow-up.
       --- End Quote ---
       The abstract can be seen here
  HTML http://www.ncbi.nlm.nih.gov/pubmed/26148120.
       *****************************************************
       Page 1 of 1